Anti-PD-1 Therapy Modulates HIV-Specific CD8+ T Cells in Men with HIV
A clinical trial of anti-PD-1 therapy in men with HIV and cancer demonstrates complex changes in HIV-specific CD8+ T-cell phenotypes and clonal distribution.
A clinical trial of anti-PD-1 therapy in men with HIV and cancer demonstrates complex changes in HIV-specific CD8+ T-cell phenotypes and clonal distribution.
PD-L1 found on the surface of cells is a well known immune checkpoint protein. When it binds to the receptor PD-1 found on the surface of T cells and B cells, it acts to suppress i...
A real-world retrospective study demonstrates that adding first-line immunotherapy to chemotherapy significantly prolongs median overall survival by 23 months in advanced SMARCA4-d...
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patient...
Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse...
Intratumoral co-administration of IL-12 and Flt3L mRNA lipid nanoparticles controlled anti-PD-1-refractory melanoma in mouse models by coordinating dendritic, natural killer, and T...
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activa...
Mumbai (Maharashtra) [India], October 12: For much of the past two decades, immunotherapy was thought of as a treatment held in reserve — an option to try after chemotherapy and ra...
Recent changes in cancer care in India show an increase in immunotherapy prescriptions due to affordable biosimilars. Doctors report that the availability of cheaper versions of ni...
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in...
Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...
HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibod...
HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-...
In mice, alcohol cut the efficacy of anti-PD-1 immunotherapy by roughly 50%, suppressing tumor-infiltrating and memory T cells while boosting TIGIT-carrying ones. Blocking TIGIT re...
A phase III trial for personalized melanoma vaccination foreshadows a new era of cancer treatment The post Personalized medicine comes to cancer immunotherapy appeared first on Pe...
A HER2-targeted mRNA lipid nanoparticle vaccine combined with fractionated radiotherapy suppressed tumor growth and reprogrammed the immune microenvironment in a mouse model of HER...
A carefully designed clinical trial that set out to supercharge the immune system’s attack on advanced melanoma has delivered a sobering but scientifically valuable verdict. Resear...
The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, wh...
An experimental oral cancer drug that disrupts a key molecular switch inside tumour cells, when paired with an established targeted therapy, has produced durable tumour shrinkage i...
First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...
Immunotherapy has transformed the treatment landscape for non-small cell lung cancer, the most common form of lung malignancy worldwide, yet a stubborn problem persists: only a sub...
One of the most stubborn obstacles in cancer immunotherapy is not the tumor cell itself but the cellular entourage that surrounds it. In hepatocellular carcinoma, the most common f...
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumorsP...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.